

Ref: FOI/GS/ID 5862

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

03 December 2019

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Juvenile Idiopathic Arthritis.

You asked:

I would like to understand how patients with juvenile ideopathic arthritis are being treated. So, in the last 6 months, how many patient(s) with juvenile ideopathic arthritis have been treated with:

Humira (adalimumab)

Amgevita (adalimumab)

Imraldi (adalimumab)

Hyrimoz (adalimumab)

Hulio (adalimumab)

Tocilizumab

Abatacept

Enbrel (etanercept)

Erelzi (etanercept)

Benepali (etanercept)

Golimumab

Remicade (infliximab)

Remsima (infliximab)

Inflectra (infliximab)

Flixabi (infliximab)

Canakinumab

Anakinra

Trust response:

Humira (adalimumab) 1

Amgevita (adalimumab) 0

Imraldi (adalimumab) 3

Hyrimoz (adalimumab) 0

Hulio (adalimumab) 0
Tocilizumab 1
Abatacept 0
Enbrel (etanercept) 0
Erelzi (etanercept) 0
Benepali (etanercept) 2
Golimumab 0
Remicade (infliximab) 0
Remsima (infliximab) 0
Inflectra (infliximab) 0
Flixabi (infliximab) 0
Canakinumab 0
Anakinra 0